Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brainHarry F. Dovey, B. Ni, Varghese John et al.|Journal of Neurochemistry|2001Cited by 879
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ DysfunctionMorie A. Gertz, Michaela Liedtke, Brendan M. Weiss et al.|Journal of Clinical Oncology|2016Cited by 206